FluoroSpot Assay Services
FluoroSpot is an advanced extension of the well-established ELISpot platform, enabling the simultaneous detection of multiple secreted analytes—most commonly cytokines—within a single assay well. Unlike traditional ELISpot assays, which measure one cytokine at a time, FluoroSpot utilizes fluorophore-labeled detection antibodies to quantify multiple cytokines in parallel, providing a more comprehensive assessment of immune function.
In a FluoroSpot assay, immune cells are stimulated in plates pre-coated with capture antibodies. As cells secrete cytokines, these molecules are captured locally on the membrane in close proximity to the originating cell. Fluorescently labeled detection antibodies subsequently bind to the captured cytokines, enabling visualization of distinct fluorescent spots. Each spot corresponds to an individual cytokine-secreting cell, allowing both qualitative and quantitative analysis of multi-functional immune responses.
FluoroSpot Assay Services
FluoroSpot is an advanced extension of the well-established ELISpot platform, enabling the simultaneous detection of multiple secreted analytes—most commonly cytokines—within a single assay well. Unlike traditional ELISpot assays, which measure one cytokine at a time, FluoroSpot utilizes fluorophore-labeled detection antibodies to quantify multiple cytokines in parallel, providing a more comprehensive assessment of immune function.
In a FluoroSpot assay, immune cells are stimulated in plates pre-coated with capture antibodies. As cells secrete cytokines, these molecules are captured locally on the membrane in close proximity to the originating cell. Fluorescently labeled detection antibodies subsequently bind to the captured cytokines, enabling visualization of distinct fluorescent spots. Each spot corresponds to an individual cytokine-secreting cell, allowing both qualitative and quantitative analysis of multi-functional immune responses.
Our Expertise
Avance Biosciences delivers validated FluoroSpot assay services for high-sensitivity, multiplexed immune response profiling. Our platform supports drug development programs from early immunogenicity risk assessment through clinical-stage immune monitoring, enabling precise evaluation of antigen-specific T cell responses, cytokine secretion profiles, and polyfunctional immune activity across discovery, preclinical, and clinical studies.
Designed for biotechnology and pharmaceutical sponsors, our FluoroSpot services maximize data output from limited PBMC samples while maintaining robust assay performance and reproducibility. We provide high-quality, reliable data packages with documentation aligned to regulatory expectations, supporting confident decision-making throughout development.
Why FluoroSpot?
- Multiplex Cytokine Detection: Quantify multiple cytokines within a single well, enabling comprehensive and efficient immune response profiling.
- Single-Cell Functional Insight: Detect cytokine secretion at the single-cell level, allowing identification of polyfunctional T cell responses.
- Efficient Use of Clinical Samples: Generate high-content data from limited PBMC samples—critical for clinical and longitudinal studies.
- Broad Drug Development Applications: Applicable across immunogenicity assessment, vaccine studies, cell and gene therapy programs, and clinical immune monitoring.
End-to-End FluoroSpot Services: Built for Regulated Programs
Avance Biosciences provides end-to-end FluoroSpot services, from multiplex panel design and assay development through validated sample analysis. Our workflows and documentation are aligned with regulatory expectations, supporting programs from early discovery through clinical development.
Methods
Description
Applications
Antigen-Specific T-Cell Response Assays
We measure CD4⁺ and CD8⁺ T cell responses following stimulation with peptide pools, recombinant proteins, vaccine antigens, or therapeutic candidates.
Vaccine development, biologic immunogenicity assessment, and gene therapy immune monitoring.
Multiplex Cytokine Profiling
Our FluoroSpot platform enables simultaneous detection of multiple cytokines within a single well, allowing detailed characterization of immune activation and functional responses.
Typical panels: IFN-γ / IL-2 / TNF-α and IFN-γ / IL-2 / IL-17A.
Immunogenicity Risk Assessment
We support evaluation of drug-induced T cell responses to assess immunogenicity risk across biologics, viral vectors, gene therapies, and mRNA therapeutics.
Candidate screening and IND-enabling studies.
Cell Therapy Functional Assays
FluoroSpot assays are used to assess cytokine secretion following activation of engineered immune cells.
CAR-T, NK cell therapies, TCR-engineered T cells, and dendritic cell vaccines.
Inflammatory / Th17 Immune Response Assays
We characterize inflammatory cytokine responses associated with immune activation and safety assessment.
Typical panels: IL-17A / TNF-α / IFN-γ.
Th2 Immune Response Assays
We evaluate Th2-associated cytokines relevant to humoral immunity and allergic responses.
Typical panels: IL-4 / IL-5 / IL-13.
Clinical Immune Monitoring
We support longitudinal immune monitoring in clinical studies, including analysis of PBMC samples collected across multiple time points.
Cryopreserved PBMC Analysis
Our validated workflows enable consistent and reliable FluoroSpot analysis of cryopreserved PBMC samples, supporting multi-site and longitudinal clinical trials.
Scalable FluoroSpot Support: Aligned with Your Program’s Stage of Development
Avance Biosciences recognizes that the value of immunogenicity data depends on both quality and timing. Our FluoroSpot services are designed to deliver stage-appropriate data packages that are immediately actionable, with workflows and documentation tailored to your program’s phase of development.
From early discovery through late-stage clinical studies, our scalable platform supports a wide range of project sizes, from rapid screening studies to large clinical sample sets, while maintaining consistent assay performance and data integrity across both regulated and non-regulated environments.
Program Stage
Challenges
Avance Solutions
Discovery & Lead Selection
De-risk candidate molecules prior to IND-enabling investment
Rapid multiplex screening panels to compare cytokine profiles across candidates, generating high-value exploratory data without full validation requirements
Preclinical / IND-Enabling
Regulatory immunogenicity risk assessment and T cell response characterization for biologics, AAV, and LNP platforms
Qualified assays supported by SOPs, validation summaries, and study reports formatted for IND submission
Phase I / Early Clinical
Monitoring T cell responses in clinical trial participants and supporting ADA follow-up characterization
Validated assay services with coordinated PBMC handling and analysis; GLP-compliant options available
Phase II / III
Large-scale sample analysis with cross-site consistency
High-throughput, validated platform with bridging strategies to ensure continuity across sites and studies
Post-Market / Lifecycle Management
Assessing impact of formulation, manufacturing changes, or biosimilar comparability
Bridging and comparability study designs anchored to validated baseline assays
FAQs
Avance supports panels targeting the most common immunogenicity-relevant cytokines including IFN-γ, IL-2, IL-4, IL-5, IL-10, IL-13, IL-17A, TNF-α, and Granzyme B, among others. Custom panels are developed based on your scientific rationale and regulatory strategy.
Yes. NHP FluoroSpot is routinely requested for IND-enabling toxicology studies and preclinical T-cell immunogenicity packages. Avance has experience optimizing assays in cynomolgus macaque PBMC matrices.
We offer both non-regulated (fit-for-purpose, appropriate for most IND-stage work) and regulated study options. The regulatory framework is scoped during study initiation and documented in the study plan.
Typical assay designs require 0.5–2 × 10⁶ PBMCs per condition. We work with your clinical operations or sample management team to design assay configurations that fit your available material, particularly where sample volume is a limiting factor in clinical studies.
Yes. Method transfers are accommodated with a defined bridging protocol. Contact us to discuss documentation requirements and timeline expectations for platform transfer projects.
Have Questions?
Discuss Your FluoroSpot Study with an Avance Scientist
Whether you’re screening candidates in discovery or looking for a validated clinical assay partner, we’re ready to discuss your timeline, sample constraints, and regulatory context. Avance Biosciences can help design a FluoroSpot strategy tailored to your program. Reach out and you’ll hear from a scientist, typically within one business day.